Muscle & Performance

A chemically modified analogue of GHRH(1-29) — the biologically active fragment of endogenous growth hormone-releasing hormone — engineered with four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that resist enzymatic degradation without extending the half-life through albumin binding. Produces a short, sharp physiologic GH pulse. Research-only; no FDA or EMA approval. Distinct from CJC-1295 DAC, which adds an albumin-binding linker and has an ~8-day half-life.

The gold-standard GH secretagogue stack in a single vial: CJC-1295 No DAC 5 mg + Ipamorelin 5 mg = 10 mg total. The two peptides drive growth-hormone release through two distinct receptor systems that are synergistic when combined. CJC-1295 No DAC activates GHRH receptors on pituitary somatotrophs, producing a short, sharp GH pulse. Ipamorelin simultaneously activates ghrelin (GHSR) receptors, amplifying the same GH pulse through a separate pathway. The two signals are synergistic — the combined GH release is significantly greater than the additive sum, because pulsatile activation of both receptor systems produces a physiologic GH pulse larger than either component alone can generate. Ipamorelin does not elevate cortisol, prolactin or ACTH — an important selectivity property that makes this blend cleaner than older ghrelin-mimetic combinations. Both components are optimally dosed at 0.1–0.15 mL per injection, both are well-characterised individually, and both are within their individually-established therapeutic ranges in the blend format.

The identical GHRH(1-29) backbone as CJC-1295 No DAC — same four amino acid substitutions, same receptor — with one additional chemical group: a maleimidopropionic acid (MPA) linker that covalently binds free serum albumin after injection. The albumin conjugation extends the plasma half-life from ~30 minutes to approximately 8 days. But it also transforms the pharmacologic signal: instead of a pulsatile GH release, the drug produces a sustained flat elevation. Not a stronger pulse — a fundamentally different drug.

A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds the ghrelin receptor GHSR-1a on pituitary somatotrophs and hypothalamic neurons, triggering GH release through a pathway parallel and additive to GHRH. Distinguished from older GH-releasing peptides (GHRP-2, GHRP-6) by selectivity: at doses producing GH release, ipamorelin does not activate the ACTH/cortisol or prolactin axes. Research-only; no FDA or EMA approval.

The shortest peptide analogue of endogenous growth hormone-releasing hormone (GHRH), consisting of amino acids 1–29 with a C-terminal amide. Binds the pituitary GHRH receptor and stimulates a short, sharp physiologic GH pulse. Historically approved by the FDA as Geref for pediatric GH deficiency in 1990; the NDA was withdrawn in 2008 for commercial reasons. Modern use is exclusively via compounding pharmacies; there is no currently marketed FDA-approved product.

A synthetic full-length analogue of growth hormone-releasing hormone (GHRH) that binds the pituitary GHRH receptor and stimulates the body's own pulsatile release of growth hormone. Research contexts include visceral fat reduction, body composition, and hepatic fat — a research-use peptide that preserves the physiologic GH pulse rather than replacing GH directly.

A two-component GH-axis research blend: Tesamorelin 5 mg + Ipamorelin 5 mg = 10 mg total. The pairing combines Tesamorelin (a stabilised GHRH analogue documented for visceral-fat reduction in the peer-reviewed GHRH-analogue literature) with Ipamorelin (a selective ghrelin-receptor agonist that adds GH pulse amplification without cortisol / prolactin / ACTH elevation). The mechanistic argument is similar to the CJC-1295 / Ipamorelin blend — dual-pathway GH stimulation — but with a Tesamorelin backbone chosen specifically for its documented visceral-fat-reduction pharmacology. The 1:1 vial ratio produces an inherent dose trade-off worth naming honestly: the 2 mg Tesamorelin research reference (0.4 mL of the reconstituted blend) delivers 1 mg of Ipamorelin — meaningfully above its optimal 0.25–0.375 mg range. The 0.2 mL compromise dose gives 0.5 mg of each — Tesamorelin below its research reference and Ipamorelin above its optimal.